von Willebrand factor: an emerging target in stroke therapy.
von Willebrand factor: an emerging target in stroke therapy.
复制标题
DOI：
10.1161/strokeaha.111.628867
复制
发表时间：
2012-02
期刊：
影响因子：
8.3
通讯作者：
Kleinschnitz C
中科院分区：
文献类型：
--
作者：
De Meyer SF;Stoll G;Wagner DD;Kleinschnitz C
血栓形成在急性缺血性脑卒中的病理生理中具有重要意义。目前用于治疗或预防脑缺血的抗血栓药物仅具有中等疗效，或有增加严重出血风险。血管性血友病因子（VWF）一直被认为是血管损伤部位血栓形成的关键因素。虽然VWF与冠心病之间的关系已经得到了很好的研究，但关于VWF在中风中的作用的知识却非常有限。然而，近年来，越来越多的临床和临床前证据揭示了VWF在脑卒中发展中的重要作用。本文综述了vwf相关过程在实验性和人体缺血性脑损伤中的病理生理作用的最新研究进展。本文讨论了vwf介导的血小板粘附和活化的新型抑制剂作为对抗包括缺血性中风在内的血栓栓塞性疾病的强大而安全的工具的潜在临床价值。
Thrombus formation is of paramount importance in the pathophysiology of acute ischemic stroke. Current antithrombotics used to treat or prevent cerebral ischemia are only moderately effective or bear an increased risk of severe bleeding. von Willebrand factor (VWF) has long been known to be a key player in thrombus formation at sites of vascular damage. While the association between VWF and coronary heart disease has been well studied, knowledge about the role of VWF in stroke is much more limited. However, in recent years, an increasing amount of clinical and preclinical evidence has revealed the critical involvement of VWF in stroke development. This review summarizes the latest insights into the pathophysiologic role of VWF-related processes in ischemic brain injury under experimental conditions and in humans. Potential clinical merits of novel inhibitors of VWF-mediated platelet adhesion and activation as powerful and safe tools to combat thromboembolic disorders including ischemic stroke are discussed.